H.C. Wainwright lowered the firm’s price target on Legend Biotech (LEGN) to $60 from $75 and keeps a Buy rating on the shares. Johnson & Johnson (JNJ) reported a Q3 sales beat for Carvykti but Legend Biotech shares had a muted reaction, the analyst tells investors in a research note. The firm believes this reflects Carvykti growth already being priced into the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech’s CARVYKTI® Receives FDA Approval for Label Update with New Survival Data
- Legend Biotech Reports Strong CARVYKTI® Sales for Q3 2025
- Johnson & Johnson Stock (JNJ) Falters Ahead of Earnings Release as Cancer Therapy Gets Warning Label
- Legend Biotech and Janssen Forge Strategic Supply Agreement
- Legend Biotech’s Strategic Positioning and Growth Potential: Overcoming Supply Constraints and Sustaining Leadership in the BCMA CAR T Space